Navigation Links
Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
Date:2/14/2013

JERUSALEM, February 14, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.

"We are very pleased to be in close and positive communications with the FDA, as well as having a clear path which meets the FDA's input. This positions us for imminent clearance from the FDA to proceed with our planned clinical studies," commented Nadav Kidron , CEO of Oramed.  

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Oramed Pharmaceuticals Announces Reverse Stock Split
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
5. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
8. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
9. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
10. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... August 01, 2014 Once a decision ... cost? This webinar will discuss how to define your ... Join speakers Bob Allen, Senior Director of Facilities Integration ... Engineering at Fluor Industrial Services, and special guest Carrier ... Planning at Amgen, as they provide an examination of ...
(Date:8/1/2014)... -- Cambrex Corporation (NYSE: CBM ) reports results ... Highlights , Second quarter sales increased 59% ... last year. , Second quarter EBITDA increased 86% to ... last year (see table at the end of this release). ... impact of foreign currency, to between 13% and 16% over ...
(Date:8/1/2014)... ON (PRWEB) August 01, 2014 ... has led to a better understanding embryonic development. ... and reorganize into structurally and functionally distinct tissues ... physical defects. Prof. Todd McDevitt, Melissa Kinney, ... biophysical signals interact with biochemical cues to control ...
(Date:7/31/2014)... August 01, 2014 “2014 ... Polyurethane Resin Industry” is a professional and ... The report introduces Polyurethane Resin basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
Breaking Biology Technology:Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Study Links Biomechanics and Gene Expression in Stem Cells 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4
... Timing of Final Analysis by One, Year While Maintaining Comparable Powering ... March 13, 2008 at 11:00 AM ... ... DNDN ) today announced that the U.S. Food and Drug Administration,(FDA) has ...
... to Improve Healing ... of ... Americas,a healthcare company focused on improving patient quality of life, ... mark for its KFH Novo medical device, a breakthrough medical,technology ...
... EMERYVILLE, Calif., March 11 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... present,at the Cowen and Company 28th Annual Health ... Eastern Time. Interested parties may access a live,webcast ... is recommended that listeners log on 15 minutes ...
Cached Biology Technology:FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 2FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 3FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 4Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device 2
(Date:8/1/2014)... examining a taxonomically confused group of marine mammals ... the Australian humpback dolphin, Sousa sahulensis , ... Enterprises. , The study describing the newly ... long systematic examination of all available historical records, ... widespread group of coastal cetaceans ranging from the ...
(Date:8/1/2014)... enormous opportunities for both biological and future clinical ... cells in the body, offering immense hope of ... kidney, liver and lung diseases and making damaged ... Prof. Jinhui Chen from Indiana University in USA ... myriad biological, ethical, legal, political, and financial challenges. ...
(Date:8/1/2014)... INDIANAPOLIS, IN August 1, 2014 The Journal ... Best Article and Best Great Educational Material (GEM) awards, ... and Behavior (SNEB) annual conference, "Nutrition Education Impact: Local ... 1, 2014. These annual awards recognize the authors ... year in JNEB, as judged by members of the ...
Breaking Biology News(10 mins):Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... 2012Epstein-Barr virus (EBV) is the cause of infectious mononucleosis ... recipients. Molecular tests that can identify early protein markers ... infection. The benefits of this diagnostic approach in patients ... in an article published in BioResearch Open Access ...
... November 13, 2012Following an infection, dysregulation of the immune ... an often fatal condition called severe sepsis or septic ... underlying immune dysfunction remain poorly understood. Regulatory T cells ... to have an important role in suppressing the immune ...
... Come rain or shine (or even snow), some glaciers ... to come. The forecast by Brigham Young University ... Bhutan, a region in the bull,s-eye of the monsoonal ... most conservative findings indicate that even if climate remained ...
Cached Biology News:Are we closer to understanding the cause of deadly sepsis? 2Himalayan glaciers will shrink even if temperatures hold steady 2
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... c-Jun proto-oncogene was first identified as the cellular ... Jun B and Jun D have been shown ... C-terminal regions, which are involved in dimerization and ... involved in transcriptional activation, diverge. ...
Biology Products: